All News about Springworks Therapeutics Inc
![](https://ml.globenewswire.com/media/03870757-75d0-4869-a7a0-98e8d7ffbc21/small/swtxlogo-jpg.jpg)
Via GlobeNewswire
![](https://www.globenewswire.com/Content/Images/intrado.png)
Via GlobeNewswire
4 Analysts Have This to Say About SpringWorks Therapeutics
December 01, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_6947.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/09/07/aapharma_9.png?width=1200&height=800&fit=crop)
SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK
September 07, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_689.png?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/10/stocks-to-buy-greedy1600-1024x576.png)
![](https://ml.globenewswire.com/media/cb189515-a53a-4aaa-bbc2-e66b4b60a4bc/small/springworks-400x400px-jpg.jpg)
![](https://ml.globenewswire.com/media/53bd4a0d-29c3-4a6a-8721-4eb69f5c3f0f/small/r-logo-color-darkfont-png.png)
![](https://ml.globenewswire.com/media/53bd4a0d-29c3-4a6a-8721-4eb69f5c3f0f/small/r-logo-color-darkfont-png.png)
![](https://cdn.benzinga.com/files/images/story/2022/07/06/aapharma_4.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://ml.globenewswire.com/media/53bd4a0d-29c3-4a6a-8721-4eb69f5c3f0f/small/r-logo-color-darkfont-png.png)
![](https://ml.globenewswire.com/media/53bd4a0d-29c3-4a6a-8721-4eb69f5c3f0f/small/r-logo-color-darkfont-png.png)
![](https://ml.globenewswire.com/media/53bd4a0d-29c3-4a6a-8721-4eb69f5c3f0f/small/r-logo-color-darkfont-png.png)
![](https://ml.globenewswire.com/media/53bd4a0d-29c3-4a6a-8721-4eb69f5c3f0f/small/r-logo-color-darkfont-png.png)
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
December 01, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/11/23/screenshot_2022-11-23_at_7.14.20_pm.png?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/53bd4a0d-29c3-4a6a-8721-4eb69f5c3f0f/small/r-logo-color-darkfont-png.png)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_2117.png?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/53bd4a0d-29c3-4a6a-8721-4eb69f5c3f0f/small/r-logo-color-darkfont-png.png)
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Exposures
COVID-19
![](https://ml.globenewswire.com/media/53bd4a0d-29c3-4a6a-8721-4eb69f5c3f0f/small/r-logo-color-darkfont-png.png)
![](https://cdn.benzinga.com/files/images/story/2022/09/13/image41.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/09/13/image-nio.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/08/11/image30.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_14477.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/08/10/image_4_1.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_7976.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/07/20/42c653e5-73c4-4bc5-a724-89e510dc932f.jpg?width=1200&height=800&fit=crop)
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.